Equillium, Inc. (EQ) - Q3 2025 Filing Summary
Business Context and Reporting Period
This summary covers Equillium, Inc.'s Form 10-Q for the quarterly period ended September 30, 2025. Equillium is a clinical-stage biotechnology company focused on developing novel therapies for severe autoimmune and inflammatory disorders. The company's primary development asset is EQ504, a novel aryl hydrocarbon receptor (AhR) modulator intended for ulcerative colitis. The company operates as a single segment and is headquartered in La Jolla, California.
Key Financial Metrics
| Metric | Q3 2025 (3 Months) | Q3 2024 (3 Months) | YTD 2025 (9 Months) | YTD 2024 (9 Months) |
|---|---|---|---|---|
| Revenue | $0 | $12.2 million | $0 | $36.7 million |
| Net Loss | $(4.2) million | $(0.01) million | $(18.6) million | $(2.3) million |
| Operating Expenses | $4.6 million | $12.8 million | $19.7 million | $40.3 million |
| Cash and Cash Equivalents | $33.1 million (as of Sept 30, 2025) | |||
| Accumulated Deficit | $212.4 million (as of Sept 30, 2025) | |||
| Weighted Avg Shares (Basic) | 65.3 million | 35.4 million | 45.7 million | 35.3 million |
Material Changes vs. Prior Period
- Revenue Cessation: Revenue dropped to zero in Q3 2025 compared to $12.2 million in Q3 2024. This is due to the expiration of the Asset Purchase Agreement with Ono Pharmaceutical Co., Ltd. on October 30, 2024, which previously provided development funding and upfront payment amortization.
- Expense Reduction: Total operating expenses decreased significantly by approximately 64% year-over-year for the quarter ($4.6M vs $12.8M). Research and Development (R&D) expenses fell from $9.6M to $1.3M, driven by the wind-down of the EQUATOR clinical study and reduced CMC activities with Biocon.
- Capital Raise: In August 2025, the company completed a private placement raising approximately $30.0 million in gross proceeds (net proceeds of $27.9 million). This included the issuance of 21.8 million shares and pre-funded warrants for 30.8 million shares.
- Share Count Increase: The weighted average shares outstanding increased from 35.4 million in Q3 2024 to 65.3 million in Q3 2025 due to the private placement and ATM sales.
Guidance, Outlook, and Risks
- Liquidity: Management believes cash and cash equivalents of $33.1 million are sufficient to fund operations for at least the next 12 months (through 2027). The company expects to incur additional losses as it advances EQ504.
- Development Plan: The company intends to commence a Phase 1 proof-of-mechanism study for EQ504 by mid-2026, with data expected approximately six months thereafter.
- Future Financing: The August 2025 Securities Purchase Agreement includes a potential second closing for up to $20.0 million, contingent on achieving specific clinical milestones (IND clearance or first patient dosing) and stock price thresholds ($2.50 VWAP).
- Strategic Shifts: The company terminated its collaboration with Biocon Limited regarding itolizumab on September 30, 2025. Additionally, the company announced a new treasury strategy in August 2025 to potentially invest in cryptocurrencies, citing volatility and regulatory risks as significant factors.
- Risks: Key risks include the need for substantial additional capital, the uncertainty of clinical trial outcomes for EQ504, potential dilution from future equity offerings, and the volatility associated with the proposed cryptocurrency treasury strategy.
Investor Verification Checklist
- Cash Runway: Verify the $33.1 million cash balance and the specific assumptions used to project operations through 2027, given the cessation of Ono funding.
- Private Placement Terms: Review the conditions for the potential $20 million milestone closing, specifically the $2.50 stock price threshold and clinical milestones required.
- Cryptocurrency Strategy: Assess the risks and potential impact of the announced cryptocurrency treasury strategy on financial stability and regulatory compliance (Investment Company Act of 1940).
- EQ504 Timeline: Monitor progress toward the mid-2026 Phase 1 study initiation and the associated budget requirements.
- Dilution Impact: Analyze the impact of the 30.8 million pre-funded warrants and the potential issuance of 35 million additional shares under the milestone closing on existing shareholder value.